Allogeneic SCT May Be Effective for Some With Advanced Cutaneous T Cell Lymphomas
the ONA take:
Allogeneic stem cell transplantation may result in long-term remissions in a subset of patients with advanced cutaneous T cell lymphomas (CTCL), a new study published online ahead of print in the journal Annals of Oncology has shown.
Because patients with advanced CTCL and large cell transformation are incurable with standard treatments, researchers from The University of Texas MD Anderson Cancer Center in Houston sought to evaluate the outcomes of patients with advanced CTCL undergoing allogeneic stem cell transplantation.
In the prospective case series, researchers report the outcomes of 47 patients with CTCL who underwent allogeneic stem cell transplantation after failure of standard therapy.
Results showed that 4-year overall survival was 51% and 4-year progression-free survival was 26%. Researchers found that 4-year progression-free survival was superior in patients who had leukemic Sézary Syndrome, a common variant of CTCL, compared with those who did not.
In regard to safety, the cumulative incidences of grades 2 to 4 acute graft-versus-host disease (GVHD) and chronic GVHD were 40% and 28%, respectively.
“Although post-SCT relapse rates are high, many patients respond to immunomodulation and achieve durable remissions,” the authors conclude.
Allogeneic stem cell transplantation may result in long-term remissions in a subset of patients with cutaneous T cell lymphomas.
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Immune Thrombocytopenia (Fact Sheet)
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|